Mesoblast Limited (LWB) Price & Analysis

4 Followers

LWB Stock Chart & Stats

€1.47

-€0.07(-5.68%)

At close: Jul 29 4:00 PM EDT

€1.47

-€0.07(-5.68%)

Day’s Range― - ―

52-Week Range€1.09 - €1.71

Previous CloseN/A

Volume0.00

Average Volume (3M)680.00

Market Cap

€1.73B

Enterprise Value€3.52K

Total Cash (Recent Filing)€47.39M

Total Debt (Recent Filing)€127.33M

Price to Earnings (P/E)―

Beta0.78

Next Earnings

Mar 04, 2027

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding1,298,748,200

10 Day Avg. Volume30

30 Day Avg. Volume680

Financial Highlights & Ratios

PEG Ratio0.61

Price to Book (P/B)3.09

Price to Sales (P/S)14.29

P/FCF Ratio-39.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€2.24

Price Target Upside52.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.01

Revenue Forecast (FY)€117.41M

Bulls Say, Bears Say

Bulls Say

Ryoncil Commercial Traction And High-margin RevenueRyoncil has quickly established a meaningful commercial revenue base, with management guiding to further growth after its first launch period. This gives Mesoblast a clearer path toward scaling its platform, while the product’s commercial adoption can support future investment in additional indications.

Broad Payer Access Supports AdoptionBroad reimbursement and treatment-center access reduce barriers to physician and patient adoption of Ryoncil. Favorable payer policies, nationwide Medicaid coverage, and growing center participation create a durable commercial foundation that can support penetration beyond the initial launch period.

Regulatory Assay Approval Strengthens Product ControlFDA approval of the new potency assay provides an additional validated tool for monitoring Ryoncil commercial lots. This regulatory progress supports ongoing product-quality oversight and may strengthen Mesoblast’s ability to maintain compliant, consistent supply as commercial volumes and future development programs expand.

Bears Say

Persistent Losses And Negative Cash GenerationMesoblast remains structurally unprofitable despite sharp revenue growth, and operating activities continue to consume substantial cash. Continued losses and negative free cash flow increase reliance on financing or future commercial execution, limiting flexibility to fund its pipeline solely from internally generated resources.

High Dependence On One ProductThe concentration of revenue in Ryoncil leaves near-term company performance heavily dependent on one product’s continued uptake and execution. Until additional indications or pipeline candidates contribute meaningful revenue, weaker-than-expected adoption or operational setbacks could materially affect Mesoblast’s growth profile.

R&D Investment Is Escalating SharplyThe substantial increase in R&D spending reflects the cost of advancing multiple clinical and regulatory programs, but it also pressures profitability and cash resources. Mesoblast must convert these investments into successful filings, approvals, and commercial products for spending intensity to translate into durable earnings improvement.

Mesoblast Limited News

Mesoblast receives FDA approval for potency assay to release Ryoncil product

Mesoblast (MESO) announced that it has received approval from the United States Food and Drug Administration, FDA, to...

1d ago

MESO

Mesoblast price target raised to $39 from $35 at Piper Sandler

Piper Sandler raised the firm’s price target on Mesoblast (MESO) to $39 from $35 and keeps an Overweight...

29d ago

MESO

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for...

2d ago

State Street Group Ceases to Be Substantial Holder in Mesoblast

Mesoblast Limited ( ($AU:MSB) ) has shared an announcement. State Street Corporation and several of its asset management...

3d ago

Mesoblast revenue surges on RYONCIL launch as late‑stage pipeline advances

Mesoblast Limited ( ($AU:MSB) ) has shared an announcement. Mesoblast reported a sharp increase in full‑year revenue to...

30d ago

Mesoblast Flags Risks Around 2026 Outlook and Stem Cell Strategy

The latest announcement is out from Mesoblast Limited ( ($AU:MSB) ). Mesoblast issued a financial results and operational...

30d ago

Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer

An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast Limited has filed its annual report...

30d ago

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Rezolve AI Ltd (RZLV)...

1M ago

HYG

Mesoblast Increases Director Philip Krause’s Equity-Based Incentives

Mesoblast Limited ( ($AU:MSB) ) just unveiled an announcement. Mesoblast Limited has disclosed a change in Director Philip...

1M ago

Mesoblast Issues 875,000 Unquoted Employee Incentive Options

Mesoblast Limited ( ($AU:MSB) ) has shared an update. Mesoblast Limited has notified the market of the issue...

1M ago

Mesoblast to Outline 2026 Results and Pipeline Progress in Investor Webcast

Mesoblast Limited ( ($AU:MSB) ) has provided an update. Mesoblast will host a webcast to discuss operational highlights...

1M ago

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: iShares US Medical Devices...

1M ago

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial...

1M ago

MESO

Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial

Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast has completed treatment of 350 patients in its...

1M ago

LWB FAQ

What was Mesoblast Limited’s price range in the past 12 months?

Mesoblast Limited lowest stock price was €1.09 and its highest was €1.71 in the past 12 months.

What is Mesoblast Limited’s market cap?

Mesoblast Limited’s market cap is €1.73B.

When is Mesoblast Limited’s upcoming earnings report date?

Mesoblast Limited’s upcoming earnings report date is Mar 04, 2027 which is in 160 days.

How were Mesoblast Limited’s earnings last quarter?

Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -€0.027 earnings per share for the quarter, missing the consensus estimate of -€0.006 by -€0.021.

Is Mesoblast Limited overvalued?

According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mesoblast Limited pay dividends?

Mesoblast Limited does not currently pay dividends.

What is Mesoblast Limited’s EPS estimate?

Mesoblast Limited’s EPS estimate is -0.01.

How many shares outstanding does Mesoblast Limited have?

Mesoblast Limited has 1,298,748,200 shares outstanding.

What happened to Mesoblast Limited’s price movement after its last earnings report?

Mesoblast Limited reported an EPS of -€0.027 in its last earnings report, missing expectations of -€0.006. Following the earnings report the stock price went down -7.752%.

Which hedge fund is a major shareholder of Mesoblast Limited?

Currently, no hedge funds are holding shares in DE:LWB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Mesoblast Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-1.48%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Mesoblast Limited

Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.

Mesoblast Limited (LWB) Earnings & Revenues

Historic Earnings Reports

LWB Stock 12 Month Forecast

Average Price Target

€2.24

▲(52.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","3":"€3","0.75":"€0.75","1.5":"€1.5","2.25":"€2.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.7431313,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.24176498,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.7876586,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,0.75,1.5,2.25,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.529,1.6223947153846152,1.7157894307692307,1.809184146153846,1.9025788615384616,1.9959735769230769,2.089368292307692,2.1827630076923077,2.276157723076923,2.3695524384615383,2.462947153846154,2.556341869230769,2.6497365846153844,{"y":2.7431313,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.529,1.5838280753846152,1.6386561507692308,1.693484226153846,1.7483123015384616,1.803140376923077,1.8579684523076923,1.9127965276923078,1.967624603076923,2.0224526784615384,2.077280753846154,2.132108829230769,2.1869369046153846,{"y":2.24176498,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.529,1.5488968153846152,1.5687936307692307,1.588690446153846,1.6085872615384615,1.6284840769230768,1.6483808923076924,1.6682777076923077,1.6881745230769232,1.7080713384615385,1.727968153846154,1.7478649692307693,1.7677617846153848,{"y":1.7876586,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.277,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.345,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.225,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.207,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.529,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >